{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T08:41:42Z","timestamp":1761986502059,"version":"3.37.3"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2017,2,4]],"date-time":"2017-02-04T00:00:00Z","timestamp":1486166400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Patient"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1007\/s40271-017-0217-0","type":"journal-article","created":{"date-parts":[[2017,2,4]],"date-time":"2017-02-04T02:01:31Z","timestamp":1486173691000},"page":"439-446","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Development of a Report Card for Identifying Local Sublingual Immunotherapy Events in Clinical Trials"],"prefix":"10.1007","volume":"10","author":[{"given":"Josephine","family":"Norquist","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emuella","family":"Flood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiffany","family":"Tanzosh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haojie","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beata","family":"Iskold","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thelma Rose","family":"Ganser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen","family":"Marson-Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,2,4]]},"reference":[{"issue":"2","key":"217_CR1","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.jaci.2013.12.1071","volume":"134","author":"PM Salo","year":"2014","unstructured":"Salo PM, Arbes SJ Jr, Jaramillo R, et al. Prevalence of allergic sensitization in the United States: results from the National Health and Nutrition Examination Survey (NHANES) 2005\u20132006. J Allergy Clin Immunol. 2014;134(2):350\u20139.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"217_CR2","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/1939-4551-7-21","volume":"7","author":"G Passalacqua","year":"2014","unstructured":"Passalacqua G. Recommendations for appropriate sublingual immunotherapy clinical trials. World Allergy Organ J. 2014;7(1):21.","journal-title":"World Allergy Organ J"},{"key":"217_CR3","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.jaci.2013.03.039","volume":"32","author":"G Passalacqua","year":"2013","unstructured":"Passalacqua G, Baena-Cagnani CE, Bousquet P, et al. Grading local side effects of sublingual immunotherapy for respiratory allergy: speaking the same language. J Allergy Clin Immunol. 2013;32:93\u20138.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"217_CR4","first-page":"6","volume":"7","author":"GW Canonica","year":"2013","unstructured":"Canonica GW, Cox L, Pawankar R, et al. Sublingual immunotherapy: World Allergy Organization position paper 2013 update. World Allergy Organ J. 2013;7(1):6.","journal-title":"World Allergy Organ J"},{"key":"217_CR5","unstructured":"US Food and Drug Administration. Guidance for industry patient-reported outcome measures: use in medical product development to support labeling claims. 2009. \n                    http:\/\/www.fda.gov\/downloads\/Drugs\/Guidances\/UCM193282.pdf\n                    \n                  . Accessed 30 Jan 2016."},{"key":"217_CR6","unstructured":"International Society for Pharmacoeconomics and Outcomes Research. Reflection paper on the regulatory guidance for the use of health-related quality of life (HRQL) measures in the evaluation of medical products. 2005. \n                    http:\/\/www.ispor.org\/workpaper\/emea-hrql-guidance.pdf\n                    \n                  . Accessed 30 Jan 2016."},{"key":"217_CR7","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1111\/j.1524-4733.2008.00470.x","volume":"12","author":"SJ Coons","year":"2009","unstructured":"Coons SJ, Gwaltney CJ, Hays RD, et al. Recommendations on evidence needed to support measurement equivalence between electronic and paper-based patient-reported outcome (PRO) measures: ISPOR ePRO Good Research Practices Task Force Report. Value Health. 2009;12:419\u201329.","journal-title":"Value Health"},{"key":"217_CR8","unstructured":"Anderson H, Wild D, Gordon-Stables R. Reviewing translatability prior to translation and linguistic validation of PROs. Poster presented at ISPOR, May 18\u201322, 2013. New Orleans, LA, USA,  2013."},{"key":"217_CR9","unstructured":"MAXQDA 11. \n                    http:\/\/www.maxqda.com\/products\/maxqda11\n                    \n                  . Accessed 20 Jan 2016."},{"issue":"3","key":"217_CR10","doi-asserted-by":"publisher","first-page":"A63","DOI":"10.1016\/j.jval.2013.03.1594","volume":"16","author":"ML Martin","year":"2013","unstructured":"Martin ML, McCarrier KP, Basse SJ, et al. Using translatability assessment to refine a patient-reported outcome (PRO) measure during the development process. Value Health. 2013;16(3):A63\u20134.","journal-title":"Value Health."},{"key":"217_CR11","unstructured":"Blum, SI, Basse, SJ, McCarrier, KP, et al. Assessing the translatability of a new patient reported outcome measure for major depressive disorder. Paper presented at the ISOQOL 20th Annual Conference; Florida; 2013. \n                    http:\/\/c-path.org\/wp-content\/uploads\/2014\/11\/assessing-the-translatability-of-a-new-patient-reported-outcome-measure-for-major-depressive-disorder.pdf\n                    \n                  . Accessed 20 Jan 2016."},{"issue":"2","key":"217_CR12","first-page":"44","volume":"29","author":"A Gnanasakthy","year":"2015","unstructured":"Gnanasakthy A, DeMuro C. Logistical considerations for integrating patient-reported outcomes in multi-regional clinical trials. Clin Researcher. 2015;29(2):44\u20138.","journal-title":"Clin Researcher."},{"issue":"4","key":"217_CR13","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.jval.2013.04.004","volume":"16","author":"LS Matza","year":"2013","unstructured":"Matza LS, Patrick D, Riley AW, et al. Pediatric patient-reported outcome instruments for research to support medical product labeling: report of the ISPOR PRO good research practices for the assessment of children and adolescents task force. Value Health. 2013;16(4):461\u201379.","journal-title":"Value Health"}],"container-title":["The Patient - Patient-Centered Outcomes Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40271-017-0217-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40271-017-0217-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40271-017-0217-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,28]],"date-time":"2019-03-28T11:07:43Z","timestamp":1553771263000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40271-017-0217-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,4]]},"references-count":13,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["217"],"URL":"https:\/\/doi.org\/10.1007\/s40271-017-0217-0","relation":{},"ISSN":["1178-1653","1178-1661"],"issn-type":[{"type":"print","value":"1178-1653"},{"type":"electronic","value":"1178-1661"}],"subject":[],"published":{"date-parts":[[2017,2,4]]},"assertion":[{"value":"4 February 2017","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Funding from Merck Sharp & Dohme was obtained by Norquist; administrative, technical, or logistic support was provided by Norquist and Tanzosh.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Josephine Norquist, Tiffany Tanzosh, Haojie Li, and Beata Iskold are employees of Merck Sharp & Dohme, who sponsored the study. Emuella Flood, Thelma Rose Ganser, and Helen Marson-Smith were employed by ICON during the study, which was paid by CRFHealth to perform the research.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}